Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University Oct 10, 2013
Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117 Sep 30, 2013
Rexahn Pharmaceuticals to Present at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9, 2013 Sep 5, 2013
Rexahn Pharmaceuticals Initiates Dosing in Phase I Trial of SupinoxinTM (RX-5902) a Candidate for Treating Solid Cancer Tumors Aug 7, 2013